PPARA and cancer: To obtain more robust data indicating that the LD–PPARα axis is necessary for the maintenance of cancer stemness, combination experiments of PPARα knockdown/GW6471 or Atglistatin/A922500 with a PPARα agonist (e.g., fenofibrate) may be useful and needed in future consideration.